Analogously, β-hCG-secreting CRC tend to exhibit poor histological differentiation, greater local invasion, and increased metastatic potential (especially to lymph nodes and the liver), leading to a worse prognosis [3,6]. Unlike CEA, which typically rises in advanced stages, β-hCG may increase in early-stage disease, and its expression can help predict recurrence risk following initial treatment [6]. Here, CEACAM5 is linked to colorectal carcinoma.